Inotiv, Inc. (FRA:BS50)

Market Cap	7.62M -94.4%
Revenue (ttm)	437.80M +8.2%
Net Income	-59.08M
EPS	-1.72
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	5
Open	0.2120
Previous Close	0.1890
Day's Range	0.1710 - 0.2120
52-Week Range	0.1710 - 4.0200
Beta	n/a
RSI	23.26
Earnings Date	Feb 5, 2026

About Inotiv

Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the ...

• Industry: Commercial Physical and Biological Research
• Founded: 1974
• Employees: 1,996
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: BS50

Financial Performance

In fiscal year 2025, Inotiv's revenue was $513.02 million, an increase of 4.54% compared to the previous year's $490.74 million. Losses were -$68.63 million, -36.72% less than in 2024.

Financial numbers in USD